50 results
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
with the amendment for its internally developed products of a similar nature; provided that such amendment shall be
timely reported to the JSC … of a similar nature; provided that such amendment shall be timely reported to the JSC and/or Subcommittee for review, as appropriate, whereby Licensee shall
6-K
CNTB
Connect Biopharma Holdings Ltd
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
or omitted.
The unaudited interim condensed consolidated financial statements include adjustments of a normal recurring nature, as necessary … to be reasonable under the circumstances.
In preparing the interim condensed consolidated financial statements, the nature of significant judgments made
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
5 Jun 23
Current report (foreign)
4:28pm
. Nature Reviews. Disease Primers. 2020. 6:74. https://doi.org/10.1038/s41572-020-0205-x Evaluate Pharma market data sourced in May 2023. Current
6-K
ga4dpbuyd54ybcmuv
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
F-3/A
2x1rw sp8
17 Jun 22
Shelf registration (foreign) (amended)
5:19pm
F-3/A
z0gei775biiwj9
20 May 22
Shelf registration (foreign) (amended)
6:54pm
6-K
EX-99.2
5qh2gm30vm1g8rdw
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
F-3
vivf4lr ljplwljczj7p
15 Apr 22
Shelf registration (foreign)
5:27pm
F-3
EX-1.2
bwf0g9wf7tcqnfk8rin
15 Apr 22
Shelf registration (foreign)
5:27pm
20-F
EX-2.5
vybbvjzl2 lydp
31 Mar 22
Annual report (foreign)
4:33pm
20-F
yw0e0xe
31 Mar 22
Annual report (foreign)
4:33pm
20-F
EX-1.1
mo42hy29g7wpcqbaki
31 Mar 22
Annual report (foreign)
4:33pm
20-F
EX-4.11
53pbtao5rl xr8c15
31 Mar 22
Annual report (foreign)
4:33pm
20-F
EX-4.10
3srfdq1yq9 n5upcjdm
31 Mar 22
Annual report (foreign)
4:33pm
20-F
EX-4.13
a40d1ghw vbk
31 Mar 22
Annual report (foreign)
4:33pm
6-K
EX-99.1
6y35f45m57wyh8obxz
19 Nov 21
Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis
4:01pm
6-K
EX-99.1
h9b 93o1rkljs
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
6-K
EX-99.2
nbqjf26xl pp4x2uf
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm